Inactief instrument

Andere talen aTyr Pharma Inc Nasdaq

Aandelen

US0021201035

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

ATyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference	15/05
ATyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis	14/05
ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis	14/05
ATyr Pharma to Present at Upcoming Investor Conferences	06/05
Atyr Pharma: Q1 Earnings Snapshot	02/05
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000	02/05
ATyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update	02/05
ATyr Pharma to Participate in April Investor Conferences	01/04
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Atyr Pharma: Q4 Earnings Snapshot	14/03
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update	14/03
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results	28/02
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants	21/02
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	21/02
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity	29/01
ATyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor	18/01
ATyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023	13/11
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen aTyr Pharma Inc Nasdaq

Aandelen

US0021201035

Andere talen

Filters